ArticleNature2023
HIV silencing and cell survival signatures in infected T cell reservoirs.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
15.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Implications and prospects of immunological and neuroimaging research in HIV-associated neurocognitive disorders.Frontiers in neurologyPooled it
- Selective persistence of HIV-1-infected T cell clones can occur through immune reprogramming driven by defective, transcriptionally active proviruses.PLoS pathogens · 2026Article
- BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.Nature microbiology · 2026Article
- Deciphering the rules of regulated cell death subroutines by in silico methods.Journal of advanced research · 2026Review
- The immunophenotype and proviral landscape of HIV-infected CD4 T cells during antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Central nervous system B cell multiomics reveals a legacy of immune dysregulation in long-term treated HIV infection.Science advances · 2026Article
- Three immunoregulatory signatures define non-productive HIV infection in stem cell memory CD4Nature communications · 2026Article
- Selective elimination of myeloid HIV reservoirs by targeting pro-survival pathways.The Journal of infection · 2026Article
- Article
- A Tissue Virus Microenvironment with Activated Stress Responses Underlies Durable SIV Persistence.bioRxiv : the preprint server for biology · 2026Article
- Three immunoregulatory signatures define non-productive HIV infection in CD4bioRxiv : the preprint server for biology · 2026Article
- HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV.Nature communications · 2026Article
- Q4ddPCR: a flexible, 4-target assay for high-resolution HIV reservoir profiling.Nature communications · 2026Article
- Interpretable inflammation landscape of circulating immune cells.Nature medicine · 2026Article
- Tools to Quantify and Characterize the Persistent Reservoir in People with HIV-1: Focus on Non-B Subtypes.Viruses · 2026Review
- The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir.PLoS pathogens · 2026Article
- Identification of Clinical Characteristics and Risk Factors of Invasive Pulmonary Aspergillosis in Patients with Acquired Immunodeficiency Syndrome: A Retrospective Study.Infection and drug resistance · 2026Article
- Development and validation of HIV SMRTcap for the characterization of HIV-1 reservoirs across tissues and subtypes.PLoS pathogens · 2026Article
- Shaping the founders: naïve CD4 T cell heterogeneity in people with HIV-1 or HIV-2.Frontiers in immunology · 2026Article
- Persistent IFN-I signaling associated with the HIV-1 reservoir fuels immune exhaustion and reveals therapeutic targets.Frontiers in immunology · 2026Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 5 institutions in 1 country.
Iain C ClarkDepartment of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9082-0253
Prakriti MudvariVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Shravan ThaplooAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Samuel SmithVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Mohammad Abu-LabanVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Mehdi HamoudaVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Marc ThebergeVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1491-4538
Sakshi ShahDepartment of Bioengineering, California Institute for Quantitative Biosciences, QB3, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-8378-7253
Sung Hee KoVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4678-7449
Liliana PérezVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Daniel G BunisHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
James S LeeHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Divya KilamVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Saami ZakariaVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9129-2093
Sally ChoiVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Samuel DarkoHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Amy R HenryHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Michael A WheelerAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0689-6384
Rebecca HohDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Salwan ButrusDepartment of Chemical and Biomolecular Engineering, California Institute for Quantitative Biosciences, QB3, University of California, Berkeley, Berkeley, CA, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6371-747X
Francisco J QuintanaAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8156-0736
Daniel C DouekHuman Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Adam R Abate *Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, San Francisco, CA, USA. arabate@gmail.com.ORCID http://orcid.org/0000-0001-9614-4831
Eli A Boritz *Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. eli.boritz@nih.gov.ORCID http://orcid.org/0000-0003-4633-4594
National Institutes of Health · USQB3 · USUniversity of California, San Francisco · USBroad Institute · USBrigham and Women's Hospital · US
Funding
Delaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9MThe Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9MHIV persistence in vivoZIAAI005131 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BORITZ, ELI · 2017 to 2025
$14.5MThe HIV ReservoirZIAAI005034 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$7.5MMulti-omic dissection of the transcriptional, epigenetic, and proteomic signatures of cells infected with latent HIVR01AI149699 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABATE, ADAM R., QUINTANA, FRANCISCO J. · 2020 to 2024
$3.8MControl of extracellular matrix remodeling by CD29+ astrocytesR01MH130458 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael Alex Wheeler · 2022 to 2026
$2.1MPathogenic Astrocyte Populations in EAE and MSR01NS129778 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI Francisco J. Quintana · 2023 to 2026
$1.7MSINGLE-CELL TRANSCRIPTOMIC ANALYSIS OF HIV-INFECTED CD4 T CELLS IN BLOOD AND LYMPHOID TISSUE USING PCR-ACTIVATED CELL SORTINGU01AI129206 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ABATE, ADAM R., BORITZ, ELI A · 2017 to 2020
$1.6MMolecular Control of Astrocytes in CNS InflammationR00NS114111 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI WHEELER, MICHAEL ALEX · 2023 to 2025
$783kSingle Cell Transcriptomic and Epigenetic Analysis of CD4 T Cells Harboring Latent HIV during Antiretroviral TherapyK22AI152644 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI CLARK, IAIN · 2021 to 2022
$264kMolecular Control of Astrocytes in CNS InflammationK99NS114111 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI WHEELER, MICHAEL ALEX · 2020 to 2021
$189kThe role of the IFNAR1/AhR signaling axis in astrocyte regulation and remediation of multiple sclerosis pathogenesisF32NS101790 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI WHEELER, MICHAEL ALEX · 2017 to 2019
$117kNIAID NIH HHS K22 AI152644NIAID NIH HHS R01 AI149699NIAID NIH HHS U01 AI129206NIAID NIH HHS UM1 AI126611NIMH NIH HHS R01 MH130458NINDS NIH HHS F32 NS101790NINDS NIH HHS K99 NS114111NINDS NIH HHS R00 NS114111NINDS NIH HHS R01 NS129778
Abstract
Rare CD4 T cells that contain HIV under antiretroviral therapy represent an important barrier to HIV cure
Indexed as
CD4-Positive T-LymphocytesGene Expression Regulation, ViralHIV-1HIV InfectionsVirus LatencyAnti-Retroviral AgentsCell ProliferationCell SurvivalDNA, ViralHumansImmunologic MemoryMicrofluidicsNecroptosisSignal TransductionTranscriptomeAnti-Retroviral AgentsDNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.